Health

International Breast Research Organization (BIG) and Roche today announced, HER2-positive (human epidermal growth factor receptor 2) women with early breast cancer in the completion of Herceptin (trastuzumab) treatment after a few years continue to be benefits. Patients to participate in the study for one year Herceptin treatment, and four years of follow-up results showed that these patients with extended disease-free survival. The HERA data updated St. Gallen in Switzerland, held in the basis of therapy for early breast cancer (Primary Therapy in Early Breast Cancer) International Conference on the release. HERA (Herceptin adjuvant therapy) studies have shown that Herceptin treatment for women to accept patients and did not receive Herceptin treatment when compared to the risk of cancer recurrence reduced by 25%. Average of 4 years after treatment, nearly 90% of the accepted treatment for women with Herceptin is still alive. In addition to significant effects, but also reported during the 4-year follow-up showed good cardiac safety and tolerability, the analysis also confirmed the long-term safety of Herceptin. "These data for the treatment of breast cancer is extremely important in terms of" HERA study researchers, International Breast Research Organization (BIG) President Dr.马丁皮卡特commented: "HERA is Herceptin HER2-positive early breast cancer treatment of the four research confirmed acceptance of the first year of Herceptin treatment can benefit patients with long-term trials. " CEO of Roche Pharmaceuticals Division, said: "HERA trial received these important long-term follow-up results, and further affirmed that Herceptin could suffer from invasive cancer of the female the opportunity to get the best cure" . The past, HER2-positive breast cancer prognosis poor, but in 2005 published the first HERA trial confirms the results of the analysis provide an unprecedented Herceptin can reduce the risk of cancer recurrence (disease-free survival) results. From the National Cancer Institute in Milan, Italy, the HERA said Principal Investigator Dr."We are pleased to see that the use of Herceptin as a drug treatment based on HER2-positive women with early breast cancer, to their future confidence. " To date, four large-scale research-HERA, NSABP B-31, NCCTG N9831 and unanimously confirmed BCIRG 006: Herceptin may be extended HER2-positive women with early breast cancer survival. Research on the HERA HERA is an international research organization breast (BIG) in collaboration with Roche, a large-scale international study of stage Ⅲ. The income group of more than 5,000 of the study is to assess patients with Herceptin adjuvant therapy for HER2-positive women with early breast cancer benefit. The study's primary endpoint is disease-free survival (DFS), secondary endpoints for overall survival (OS) and cardiac safety. HERA study is underway and is expected in 2011 will be the final result.